Search

Displaying results 7341 - 7350 of 8696 in total
  1. Drug

    Becatecarin

    go.drugbank.com/drugs/DB06362
    Investigational

    Becatecarin is a derivative of rebeccamycin.

  2. Drug

    Parsatuzumab

    go.drugbank.com/drugs/DB14897
    Investigational

    Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for

  3. Drug

    AS-8112

    go.drugbank.com/drugs/DB09207
    Experimental

    It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use. … AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.

    Categories: Dopamine D2 Receptor Antagonists
  4. Drug

    Argan oil

    go.drugbank.com/drugs/DB14310
    Investigational

    It is not an approved drug.

  5. Drug

    Macadamia oil

    go.drugbank.com/drugs/DB14330
    Investigational

    It is not an approved drug.

  6. Drug

    Tribulus terrestris

    go.drugbank.com/drugs/DB14358
    Investigational

    It is not an approved drug.

  7. Drug

    LV305

    go.drugbank.com/drugs/DB17288
    Investigational

    LV305 is an active component of CMB305 along with [G305].[L47346]

  8. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. … The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived

  9. Drug

    Maduramicin

    go.drugbank.com/drugs/DB11525
    ExperimentalVet approved

    Maduramicin is an antiprotozoal agent used in veterinary medicine as prophylaxis against coccidiosis.

  10. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.